For the quarter ending 2025-09-30, LXEO made $23,104,000 in revenue. -$20,283,000 in net income. Net profit margin of -87.79%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| Research and development | 15,695,000 | 14,721,000 | 18,522,750 | |
| General and administrative | 5,953,000 | 15,967,000 | 7,918,750 | |
| Total operating expenses | 21,648,000 | 30,688,000 | 26,441,500 | |
| Operating loss | -21,648,000 | -30,688,000 | -26,441,500 | |
| Accretion of discount on investments | - | - | 5,750 | |
| Other income (expense), net | -9,000 | -14,000 | -2,250 | |
| Interest expense | 22,000 | 25,000 | 34,250 | |
| Interest income | 1,456,000 | 1,268,000 | 1,889,000 | |
| Gain on long-term investment | - | 3,390,000 | - | |
| Amortization of premium on investments in u.s. treasury securities | 60,000 | 34,000 | - | |
| Total other income and expense | 1,365,000 | 4,585,000 | 1,858,250 | |
| Loss from operations before income taxes | -20,283,000 | -26,103,000 | -24,583,250 | |
| Net loss | -20,283,000 | -26,103,000 | -24,583,250 | |
| Earnings per share, basic | -0.33 | -0.6 | -0.773 | |
| Net loss per common share, diluted | -0.33 | -0.6 | -0.773 | |
| Weighted-average common shares outstanding, basic | 60,980,867 | 43,573,628 | 7,946,872.75 | |
| Weighted-average common shares outstanding, diluted | 60,980,867 | 43,573,628 | 7,946,872.75 | |
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)